AbbVie reported mixed Q2 2024 results, adding to my concerns of its growth potential. Looking ahead, I see continued pressure for Humira sales and also increasing in-house R&D expenses. These issues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback